Cargando…

Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus

SLE is a clinically heterogeneous disease characterized by an unpredictable relapsing-remitting disease course. Although the etiology and mechanisms of SLE flares remain elusive, Epstein-Barr virus (EBV) reactivation is implicated in SLE pathogenesis. This study examined the relationships between se...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Rebecca A., Guthridge, Lauren, Thurmond, Emma, Guthridge, Carla J., Kheir, Joseph M., Bourn, Rebecka L., Wagner, Catriona A., Chen, Hua, DeJager, Wade, Macwana, Susan R., Kamp, Stan, Lu, Rufei, Arriens, Cristina, Chakravarty, Eliza F., Thanou, Aikaterini, Merrill, Joan T., Guthridge, Joel M., James, Judith A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716608/
https://www.ncbi.nlm.nih.gov/pubmed/35005588
http://dx.doi.org/10.1016/j.jtauto.2021.100117
_version_ 1784624359856406528
author Wood, Rebecca A.
Guthridge, Lauren
Thurmond, Emma
Guthridge, Carla J.
Kheir, Joseph M.
Bourn, Rebecka L.
Wagner, Catriona A.
Chen, Hua
DeJager, Wade
Macwana, Susan R.
Kamp, Stan
Lu, Rufei
Arriens, Cristina
Chakravarty, Eliza F.
Thanou, Aikaterini
Merrill, Joan T.
Guthridge, Joel M.
James, Judith A.
author_facet Wood, Rebecca A.
Guthridge, Lauren
Thurmond, Emma
Guthridge, Carla J.
Kheir, Joseph M.
Bourn, Rebecka L.
Wagner, Catriona A.
Chen, Hua
DeJager, Wade
Macwana, Susan R.
Kamp, Stan
Lu, Rufei
Arriens, Cristina
Chakravarty, Eliza F.
Thanou, Aikaterini
Merrill, Joan T.
Guthridge, Joel M.
James, Judith A.
author_sort Wood, Rebecca A.
collection PubMed
description SLE is a clinically heterogeneous disease characterized by an unpredictable relapsing-remitting disease course. Although the etiology and mechanisms of SLE flares remain elusive, Epstein-Barr virus (EBV) reactivation is implicated in SLE pathogenesis. This study examined the relationships between serological measures of EBV reactivation, disease activity, and interferon (IFN)-associated immune pathways in SLE patients. Sera from adult SLE patients (n = 175) and matched unaffected controls (n = 47) were collected and tested for antibodies against EBV-viral capsid antigen (EBV-VCA; IgG and IgA), EBV-early antigen (EBV-EA; IgG), cytomegalovirus (CMV; IgG), and herpes simplex virus (HSV-1; IgG). Serological evidence of EBV reactivation was more common in SLE patients compared to controls as demonstrated by seropositivity to EBV-EA IgG (39% vs 13%; p = 0.0011) and EBV-VCA IgA (37% vs 17%; p = 0.018). EBV-VCA, CMV1, and HSV-1 IgG seropositivity rates did not differ between SLE patients and controls. Furthermore, concentrations of EBV-VCA (IgG and IgA) and EBV-EA (IgG) were higher in SLE patients. SLE patients with high disease activity had increased concentrations of EBV-VCA IgA (mean ISR 1.34 vs. 0.97; p = 0.041) and EBV-EA IgG levels (mean ISR 1.38 vs. 0.90; p = 0.007) compared with those with lower disease activity. EBV reactivation was associated with enhanced levels of the IFN-associated molecule IP-10 (p < 0.001) and the soluble mediators BLyS (p < 0.001) and IL-10 (p = 0.0011). In addition, EBV-EA IgG responses were enriched in two previously defined patient clusters with robust expression of IFN and inflammatory or lymphoid and monocyte responses. Patients in these clusters were also more likely to have major organ involvement, such as renal disease. This study supports a possible role for EBV reactivation in SLE disease activity.
format Online
Article
Text
id pubmed-8716608
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87166082022-01-06 Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus Wood, Rebecca A. Guthridge, Lauren Thurmond, Emma Guthridge, Carla J. Kheir, Joseph M. Bourn, Rebecka L. Wagner, Catriona A. Chen, Hua DeJager, Wade Macwana, Susan R. Kamp, Stan Lu, Rufei Arriens, Cristina Chakravarty, Eliza F. Thanou, Aikaterini Merrill, Joan T. Guthridge, Joel M. James, Judith A. J Transl Autoimmun Research paper SLE is a clinically heterogeneous disease characterized by an unpredictable relapsing-remitting disease course. Although the etiology and mechanisms of SLE flares remain elusive, Epstein-Barr virus (EBV) reactivation is implicated in SLE pathogenesis. This study examined the relationships between serological measures of EBV reactivation, disease activity, and interferon (IFN)-associated immune pathways in SLE patients. Sera from adult SLE patients (n = 175) and matched unaffected controls (n = 47) were collected and tested for antibodies against EBV-viral capsid antigen (EBV-VCA; IgG and IgA), EBV-early antigen (EBV-EA; IgG), cytomegalovirus (CMV; IgG), and herpes simplex virus (HSV-1; IgG). Serological evidence of EBV reactivation was more common in SLE patients compared to controls as demonstrated by seropositivity to EBV-EA IgG (39% vs 13%; p = 0.0011) and EBV-VCA IgA (37% vs 17%; p = 0.018). EBV-VCA, CMV1, and HSV-1 IgG seropositivity rates did not differ between SLE patients and controls. Furthermore, concentrations of EBV-VCA (IgG and IgA) and EBV-EA (IgG) were higher in SLE patients. SLE patients with high disease activity had increased concentrations of EBV-VCA IgA (mean ISR 1.34 vs. 0.97; p = 0.041) and EBV-EA IgG levels (mean ISR 1.38 vs. 0.90; p = 0.007) compared with those with lower disease activity. EBV reactivation was associated with enhanced levels of the IFN-associated molecule IP-10 (p < 0.001) and the soluble mediators BLyS (p < 0.001) and IL-10 (p = 0.0011). In addition, EBV-EA IgG responses were enriched in two previously defined patient clusters with robust expression of IFN and inflammatory or lymphoid and monocyte responses. Patients in these clusters were also more likely to have major organ involvement, such as renal disease. This study supports a possible role for EBV reactivation in SLE disease activity. Elsevier 2021-08-31 /pmc/articles/PMC8716608/ /pubmed/35005588 http://dx.doi.org/10.1016/j.jtauto.2021.100117 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research paper
Wood, Rebecca A.
Guthridge, Lauren
Thurmond, Emma
Guthridge, Carla J.
Kheir, Joseph M.
Bourn, Rebecka L.
Wagner, Catriona A.
Chen, Hua
DeJager, Wade
Macwana, Susan R.
Kamp, Stan
Lu, Rufei
Arriens, Cristina
Chakravarty, Eliza F.
Thanou, Aikaterini
Merrill, Joan T.
Guthridge, Joel M.
James, Judith A.
Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus
title Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus
title_full Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus
title_fullStr Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus
title_full_unstemmed Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus
title_short Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus
title_sort serologic markers of epstein-barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus
topic Research paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716608/
https://www.ncbi.nlm.nih.gov/pubmed/35005588
http://dx.doi.org/10.1016/j.jtauto.2021.100117
work_keys_str_mv AT woodrebeccaa serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT guthridgelauren serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT thurmondemma serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT guthridgecarlaj serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT kheirjosephm serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT bournrebeckal serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT wagnercatrionaa serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT chenhua serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT dejagerwade serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT macwanasusanr serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT kampstan serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT lurufei serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT arrienscristina serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT chakravartyelizaf serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT thanouaikaterini serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT merrilljoant serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT guthridgejoelm serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus
AT jamesjuditha serologicmarkersofepsteinbarrvirusreactivationareassociatedwithincreaseddiseaseactivityinflammationandinterferonpathwayactivationinpatientswithsystemiclupuserythematosus